Industry
Biotechnology
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Loading...
Open
15.52
Mkt cap
507M
Volume
688K
High
17.31
P/E Ratio
-2.75
52-wk high
41.31
Low
15.32
Div yield
N/A
52-wk low
14.20
Portfolio Pulse from
December 12, 2024 | 3:30 pm
Portfolio Pulse from
December 11, 2024 | 2:00 pm
Portfolio Pulse from
December 11, 2024 | 1:45 pm
Portfolio Pulse from
November 25, 2024 | 4:00 pm
Portfolio Pulse from
November 08, 2024 | 6:15 pm
Portfolio Pulse from
November 05, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 9:38 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.